$4.20
+5.3%Opus Genetics, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. The company offers Phentolamine Ophthalmic Solution for reversal of mydriasis, as well as is in Phase III clinical trials for presbyopia and dim light or night vision disturbances. Its lead retinal product candidate is APX3330, a small-molecule inhibitor of reduction oxidation effector factor-1 protein that has completed Phase II clinical trial for the treatment of diabetic retinopathy. The company also develops APX2009 and APX2014 that are preclinical product candidates for retina indications. The company was formerly known as Ocuphire Pharma, Inc. Opus Genetics, Inc. was founded in 2018 and is headquartered in Farmington Hills, Michigan.
Chief Executive Officer & Director
Compensation
$889,238
Chief Financial Officer
Compensation
$575,916
Chief Operating Officer
Chief Scientific & Development Officer
Compensation
$565,368
Director & Corporate Controller
Head of Market Development & Commercialization
President & Director
Senior Vice President of Corporate Development & Secretary
Compensation
$434,100
Senior Vice President of Finance
Compensation
$434,100
During the last 12 months, insiders have purchased $1.26M and sold $16.49M worth of IRD shares, resulting in $15.23M of net selling activity.
0
0.00
1.8M
7.78M
-7.8M
-$7.78M
81.0K
160.27K
4.0M
8.60M
-8.4M
-$8.44M
0
0.00
54.1K
116.20K
-116K
-$116K
956.5K
1.10M
0
0.00
+1.1M
+$1.10M
Gallagher Cam
Director
$1.16M
Ainsworth Sean
Director
$100K
Foundation Fighting Blindness Retinal Degeneration Fund
Director, Other: See Remarks
$15.99M
Magrath George
Director, Officer: Chief Executive Officer
$247K
Yerxa Benjamin R
Director, Officer: President
$86K
Jayagopal Ashwath
Officer: Chief Scientific & Dev. Ofc.
$58K
Schachle Joseph K
Officer: Chief Operating Officer
$44K
Strong bearish signal with $15.23M net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Very poor ratio. Heavy selling with minimal buying suggests insiders may be concerned about valuation or outlook.
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
5 insider sellers vs. 2 buyers. Widespread selling across multiple insiders may signal concerns.
Multiple red flags: Heavy selling, numerous sellers, and continued recent selling create a concerning pattern. Investigate fundamental drivers and consider whether company guidance or industry conditions have deteriorated.
IRD - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | March 23, 2026 | April 20, 2026 | 2026 | |
DEF 14A DEF 14A 2024 N/A | April 29, 2024 | June 11, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | May 01, 2023 | June 06, 2023 | 2023 | |
DEF 14A DEF 14A 2022 N/A | April 27, 2022 | June 13, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | April 26, 2021 | June 07, 2021 | 2021 | |
DEF 14A DEF 14A 2019 N/A | April 29, 2019 | June 06, 2019 | 2019 | |
DEF 14A DEF 14A 2019 N/A | February 14, 2019 | March 26, 2019 | 2019 | |
DEF 14A DEF 14A 2018 N/A | July 23, 2018 | August 30, 2018 | 2018 | |
DEF 14A DEF 14A 2018 N/A | April 23, 2018 | June 14, 2018 | 2018 | |
DEF 14A DEF 14A 2017 N/A | February 24, 2017 | April 11, 2017 | 2017 |
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.